hyaluronidase 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
enzymes	5033	9001-54-1

Description:

Molecule	Description
Synonyms: hyaluronidase recombinant human hyaluronidase wydase hyaluronidase ovine hyaluronidase bovine vorhyaluronidase alfa (genetical recombination)	An enzyme that catalyzes the random hydrolysis of 1,4-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate. (From Enzyme Nomenclature, 1992) There has been use as ANTINEOPLASTIC AGENTS to limit NEOPLASM METASTASIS. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

hyaluronidase recombinant human
hyaluronidase
wydase
hyaluronidase ovine
hyaluronidase bovine
vorhyaluronidase alfa (genetical recombination)

An enzyme that catalyzes the random hydrolysis of 1,4-linkages between N-acetyl-beta-D-glucosamine and D-glucuronate residues in hyaluronate. (From Enzyme Nomenclature, 1992) There has been use as ANTINEOPLASTIC AGENTS to limit NEOPLASM METASTASIS.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
March 22, 1950	FDA	BAXTER HLTHCARE
Aug. 25, 2021	PMDA	Janssen Pharmaceutical, K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Parophthalmia	96.78	28.11	16	2726	307	63485973
Purtscher retinopathy	91.42	28.11	13	2729	85	63486195
Conjunctival oedema	71.96	28.11	14	2728	688	63485592
Exophthalmos	55.88	28.11	13	2729	1503	63484777
Product administered at inappropriate site	55.72	28.11	15	2727	3134	63483146
Lagophthalmos	48.03	28.11	9	2733	361	63485919
Blood phosphorus increased	46.46	28.11	13	2729	3132	63483148
Protein total decreased	38.24	28.11	13	2729	5964	63480316
Deep vein thrombosis postoperative	36.82	28.11	15	2727	11354	63474926
Hypernatraemia	35.17	28.11	13	2729	7596	63478684
Sensory loss	34.85	28.11	14	2728	10224	63476056
Rectal haemorrhage	34.06	28.11	23	2719	49007	63437273
Autoimmune disorder	30.88	28.11	15	2727	17162	63469118

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Parophthalmia	95.71	29.01	16	2980	381	79741011
Purtscher retinopathy	89.97	29.01	13	2983	113	79741279
Lagophthalmos	87.11	29.01	15	2981	428	79740964
Product administered at inappropriate site	59.02	29.01	16	2980	3949	79737443
Exophthalmos	55.97	29.01	13	2983	1717	79739675
Conjunctival oedema	55.51	29.01	12	2984	1146	79740246
Strabismus	46.22	29.01	12	2984	2509	79738883
Deep vein thrombosis postoperative	39.66	29.01	15	2981	10737	79730655
Cellulitis orbital	36.72	29.01	8	2988	791	79740601
Protein total decreased	34.68	29.01	13	2983	9079	79732313
Sensory loss	33.51	29.01	14	2982	12977	79728415
Autoimmune disorder	33.35	29.01	15	2981	16597	79724795
Blood phosphorus increased	33.04	29.01	13	2983	10334	79731058
Retinal artery occlusion	29.72	29.01	9	2987	3285	79738107

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B06AA03	BLOOD AND BLOOD FORMING ORGANS OTHER HEMATOLOGICAL AGENTS OTHER HEMATOLOGICAL AGENTS Enzymes
FDA CS	M0009499	Glycoside Hydrolases
FDA EPC	N0000175531	Endoglycosidase

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Systemic AL amyloidosis	indication	23132008
Multiple myeloma	indication	109989006	DOID:9538
Subcutaneous clysis of patient for fluid administration	indication	113154008

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
D04456	KEGG_DRUG
4018028	VUID
N0000146371	NUI
4018028	VANDF
C0020197	UMLSCUI
CHEMBL1201636	ChEMBL_ID
91820602	PUBCHEM_CID
DB14740	DRUGBANK_ID
CHEMBL1201718	ChEMBL_ID
CHEMBL2108607	ChEMBL_ID
DB06205	DRUGBANK_ID
1300478	RXNORM
1312	MMSL
4832	MMSL
63625	MMSL
d01393	MMSL
001887	NDDF
010831	NDDF
011274	NDDF
387280008	SNOMEDCT_US
420670008	SNOMEDCT_US
420993004	SNOMEDCT_US
51132001	SNOMEDCT_US
784400007	SNOMEDCT_US
786123000	SNOMEDCT_US
D006821	MESH_DESCRIPTOR_UI

Pharmaceutical products:

None